Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 8 | 2023 | 2138 | 1.210 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 115 | 0.670 |
Why?
|
| Frailty | 2 | 2024 | 113 | 0.410 |
Why?
|
| Veterans | 5 | 2024 | 1641 | 0.380 |
Why?
|
| Wearable Electronic Devices | 2 | 2024 | 105 | 0.360 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 1429 | 0.340 |
Why?
|
| HIV Infections | 2 | 2018 | 2134 | 0.330 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 393 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5178 | 0.240 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 64 | 0.220 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 10 | 0.210 |
Why?
|
| Dexamethasone | 3 | 2023 | 1450 | 0.200 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 833 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 1249 | 0.160 |
Why?
|
| Chromatin | 1 | 2022 | 942 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2019 | 291 | 0.140 |
Why?
|
| Paraproteinemias | 1 | 2016 | 61 | 0.140 |
Why?
|
| Motor Activity | 1 | 2019 | 693 | 0.130 |
Why?
|
| Neoplasms | 4 | 2024 | 15193 | 0.120 |
Why?
|
| Hospitalization | 1 | 2022 | 2083 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2015 | 176 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2021 | 32848 | 0.100 |
Why?
|
| Humans | 20 | 2024 | 261506 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1870 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14289 | 0.090 |
Why?
|
| Gait | 2 | 2021 | 165 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2015 | 610 | 0.080 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 188 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 15862 | 0.080 |
Why?
|
| Myocardium | 1 | 2015 | 1313 | 0.080 |
Why?
|
| Bortezomib | 2 | 2023 | 543 | 0.080 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2007 | 22 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2023 | 605 | 0.080 |
Why?
|
| Aged | 10 | 2024 | 70117 | 0.080 |
Why?
|
| Phosphatidylserines | 1 | 2007 | 68 | 0.080 |
Why?
|
| Phagocytosis | 1 | 2007 | 260 | 0.070 |
Why?
|
| Azacitidine | 1 | 2011 | 1149 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2007 | 1008 | 0.060 |
Why?
|
| United States | 4 | 2023 | 15433 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 339 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10035 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 891 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2016 | 2979 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2023 | 118 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 6915 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2021 | 22 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 231 | 0.050 |
Why?
|
| Rural Population | 1 | 2023 | 281 | 0.050 |
Why?
|
| Genes, myc | 1 | 2022 | 358 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2011 | 2669 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 589 | 0.040 |
Why?
|
| Fear | 1 | 2021 | 254 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 7702 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 142 | 0.040 |
Why?
|
| Male | 6 | 2019 | 123000 | 0.040 |
Why?
|
| Adult | 3 | 2022 | 77950 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 29902 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 3719 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 151 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 1274 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 86204 | 0.030 |
Why?
|
| Exercise | 1 | 2024 | 1183 | 0.030 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2015 | 31 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 2352 | 0.030 |
Why?
|
| Autografts | 1 | 2015 | 165 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2015 | 136 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 761 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2015 | 362 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 5047 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2015 | 598 | 0.030 |
Why?
|
| Survival Rate | 2 | 2016 | 12221 | 0.030 |
Why?
|
| Pyrazines | 1 | 2015 | 495 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 351 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1363 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1085 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 687 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1182 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6100 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2015 | 1145 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 9244 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 1360 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2007 | 45 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 4988 | 0.020 |
Why?
|
| Female | 4 | 2019 | 141928 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4744 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2007 | 339 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 783 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 1489 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7548 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 21713 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 10001 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 3438 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 13658 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 37905 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 4367 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 34495 | 0.000 |
Why?
|
| Animals | 1 | 2007 | 59536 | 0.000 |
Why?
|